Cervavac HPV Vaccine Gets WHO Prequalification: Boost for India
Serum Institute of India's Cervavac vaccine has received a major international approval, paving the way for its global use.
Source: GNews India BiotechThe World Health Organization (WHO) has granted prequalification to Cervavac, India's first indigenously developed Quadrivalent Human Papillomavirus (qHPV) vaccine. This significant milestone allows Cervavac to be procured by UN agencies and Gavi, the Vaccine Alliance, for global immunization programs. Developed by the Serum Institute of India (SII) in collaboration with the Department of Biotechnology (DBT), Cervavac aims to protect against cervical cancer. The vaccine was launched in India in January 2023. WHO prequalification ensures that vaccines meet international standards of quality, safety, and efficacy, making them eligible for supply to countries worldwide. This approval is expected to significantly boost India's efforts in cervical cancer prevention and make the vaccine more accessible and affordable globally.
This news is important for competitive exams under Science & Technology (UPSC GS Paper III, SSC General Science). Aspirants should know about indigenous vaccine development, the role of WHO prequalification, and public health initiatives against diseases like cervical cancer. It highlights India's growing capabilities in biotechnology and its contribution to global health.
- Cervavac is India's first indigenously developed Quadrivalent Human Papillomavirus (qHPV) vaccine.
- The vaccine received WHO prequalification, making it eligible for global procurement.
- It was developed by Serum Institute of India (SII) and the Department of Biotechnology (DBT).
- Cervavac was launched in India in January 2023.
- The vaccine targets the prevention of cervical cancer.
- WHO prequalification ensures vaccines meet international standards for quality, safety, and efficacy.
Cervavac is India's first domestically developed Quadrivalent Human Papillomavirus (qHPV) vaccine. It was developed by the Serum Institute of India (SII) in partnership with the Department of Biotechnology (DBT). The vaccine is designed to protect against various strains of HPV that cause cervical cancer and other related diseases. It represents a significant step in India's self-reliance in vaccine production.
WHO Prequalification is a service provided by the World Health Organization to assess the quality, safety, and efficacy of health products. For vaccines, it means they meet international standards and can be procured by UN agencies and Gavi, the Vaccine Alliance. This process helps ensure that safe and effective health products are available globally, especially in low- and middle-income countries.
Human Papillomavirus (HPV) is a common group of viruses. Some types of HPV can cause warts, while others can lead to certain types of cancer, most notably cervical cancer. HPV is primarily transmitted through sexual contact. Vaccines like Cervavac are designed to prevent infection from the high-risk types of HPV, thereby reducing the incidence of associated cancers.
Founded in 1966 by Cyrus Poonawalla, the Serum Institute of India (SII) is the world's largest vaccine manufacturer by dose. Headquartered in Pune, India, it produces a wide range of vaccines for various diseases. SII plays a crucial role in global health by supplying affordable vaccines to numerous countries and is a key partner for organizations like WHO and UNICEF.
Exams often ask about India's indigenous scientific achievements, major health initiatives, and the roles of international organizations like WHO. Focus on the 'firsts' and the impact on public health.
Remember 'Cerva-vac' for 'Cervical Vaccine' and 'WHO-PQ' for 'World Health Organization Prequalification' a global quality stamp.
Frequently Asked Questions
What is Cervavac and why is its WHO prequalification important?
Cervavac is India's first indigenous Quadrivalent Human Papillomavirus (qHPV) vaccine, developed by Serum Institute of India. Its WHO prequalification is crucial because it allows UN agencies and Gavi to procure the vaccine for global immunization programs, making it accessible worldwide and boosting India's role in global health.
Which organizations developed Cervavac and when was it launched in India?
Cervavac was developed by the Serum Institute of India (SII) in collaboration with the Department of Biotechnology (DBT). It was officially launched in India in January 2023, marking a significant step in domestic vaccine production for cervical cancer prevention.
What is the primary purpose of the Cervavac vaccine?
The primary purpose of the Cervavac vaccine is to prevent cervical cancer, which is largely caused by certain types of Human Papillomavirus (HPV). By targeting these high-risk HPV strains, the vaccine aims to reduce the incidence and mortality associated with cervical cancer globally.
